-+ 0.00%
-+ 0.00%
-+ 0.00%

Rigel Pharmaceuticals Lowers FY2026 Sales Guidance from $275.000M-$290.000M to $255.000M-$265.000M

Benzinga·03/03/2026 21:45:04
Listen to the news
Rigel Pharmaceuticals (NASDAQ:RIGL) lowers FY2026 sales outlook from $275.000 million-$290.000 million to $255.000 million-$265.000 million.